• Home

  • Documents

  • web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... ·...
19

web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers

Embed Size (px)

Citation preview

Page 1: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 2: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 3: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 4: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 5: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 6: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 7: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 8: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 9: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 10: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 11: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 12: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 13: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 14: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 15: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 16: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 17: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 18: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers
Page 19: web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C04... · Presented by-Hans-Joachim Schmoll p = 0,085 (sign. < 0.1) 0,16 2017 Gastrointestinal Cancers

Slide 2 / 17web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-0… · slide 9 / 17 slide 10 / 17 page 5. undefined s5-05 trastuzumab emtansine improves overall survival

Slide 2 / 17web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-0… · slide 9 / 17 slide 10 / 17 page 5. undefined s5-05 trastuzumab emtansine improves overall survival

Documents
Folie001 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/STGALLEN/2... · Characterization of primary tumors Beckman-Coulter Brahms Diapat/Mosaiques DiaSorin Epigenomics

Folie001 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/STGALLEN/2... · Characterization of primary tumors Beckman-Coulter Brahms Diapat/Mosaiques DiaSorin Epigenomics

Documents
OPERATING WEIGHT 0,035 - 0,085 m3 PC20MR-2...Komatsu Europe International NV Mechelsesteenweg 586 B-1800 VILVOORDE (BELGIUM) Tel. +32-2-255 24 11 Fax +32-2-252 19 81 Materials and

OPERATING WEIGHT 0,035 - 0,085 m3 PC20MR-2...Komatsu Europe International NV Mechelsesteenweg 586 B-1800 VILVOORDE (BELGIUM) Tel. +32-2-255 24 11 Fax +32-2-252 19 81 Materials and

Documents
SABCS 2013 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · 'One P30+DOC randomized patient received RAM DOC n Cycle I only therefore is included in the RAM DOC

SABCS 2013 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · 'One P30+DOC randomized patient received RAM DOC n Cycle I only therefore is included in the RAM DOC

Documents
Pretreatment with Prasugrel in Non ST-Segment Elevation ...web.oncoletter.ch/files/cto_layout/Kongressdateien/ECCO ESMO 201… · sponsored by Daiichi Sankyo and Eli Lilly, and was

Pretreatment with Prasugrel in Non ST-Segment Elevation ...web.oncoletter.ch/files/cto_layout/Kongressdateien/ECCO ESMO 201… · sponsored by Daiichi Sankyo and Eli Lilly, and was

Documents
OPERATING WEIGHT 0,035 - 0,085 m3 PC20MR-2

OPERATING WEIGHT 0,035 - 0,085 m3 PC20MR-2

Documents
SABCS 2016web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2016/SLID… · Double-blind Concordance Study of Breast Cancer Recommendations Between Manipal Multidisc* Tumor

SABCS 2016web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2016/SLID… · Double-blind Concordance Study of Breast Cancer Recommendations Between Manipal Multidisc* Tumor

Documents
SABCS 2016 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien... · SABCS 2016. Disclosure of Potential Conflicts of Interest Employment: Immediate Family Member Sandoz

SABCS 2016 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien... · SABCS 2016. Disclosure of Potential Conflicts of Interest Employment: Immediate Family Member Sandoz

Documents
oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer

oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer

Documents
Slide 2 / 28web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S6-0… · slide 1 / 28 slide 2 / 28 page 1. undefined s6-04 patient-reported outcome (pro) results, nrg oncology/nsabp

Slide 2 / 28web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S6-0… · slide 1 / 28 slide 2 / 28 page 1. undefined s6-04 patient-reported outcome (pro) results, nrg oncology/nsabp

Documents
SABCS 2016 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2016/SLID… · -2016 DEC. 6-10 SAN ANTONIO BREAST CANCER SYMPOSIUM Financial disclosure: Consultancy

SABCS 2016 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2016/SLID… · -2016 DEC. 6-10 SAN ANTONIO BREAST CANCER SYMPOSIUM Financial disclosure: Consultancy

Documents
SABCS 2016web.oncoletter.ch/files/cto_layout/Kongressdateien... · 2016. 12. 10. · First study with CellSearch@, N=118 pts (REMAGUS02) No significant association between CTC detection

SABCS 2016web.oncoletter.ch/files/cto_layout/Kongressdateien... · 2016. 12. 10. · First study with CellSearch@, N=118 pts (REMAGUS02) No significant association between CTC detection

Documents
Stage 1: Policy - Camping Laguna · Rati 2017 (L) Rati Evolution 17-18 TOTAL 16.917 0,086 16.861 0,085 17.693 0,088 18.213 0,089 1,89%. 5 Diesel Oil Supply for hot water in sanitary

Stage 1: Policy - Camping Laguna · Rati 2017 (L) Rati Evolution 17-18 TOTAL 16.917 0,086 16.861 0,085 17.693 0,088 18.213 0,089 1,89%. 5 Diesel Oil Supply for hot water in sanitary

Documents
web.oncoletter.chweb.oncoletter.ch/.../WCGIC2016_SessionXV_3Moehler.pdf · Review 0.8 45 'p/ete response response 14, 33 1. 11 . 30 11 ... I. Kaufman at ASCO 2016 Abstract 2 et Poster

web.oncoletter.chweb.oncoletter.ch/.../WCGIC2016_SessionXV_3Moehler.pdf · Review 0.8 45 'p/ete response response 14, 33 1. 11 . 30 11 ... I. Kaufman at ASCO 2016 Abstract 2 et Poster

Documents
Slide 2 / 20 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-07.… · NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028 Speaker: Hope S Rugo Slide

Slide 2 / 20 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-07.… · NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028 Speaker: Hope S Rugo Slide

Documents
great design · 137004-003 GRIGIO/GREY RAL7003 x1 10 telaio tubo/tube frame 0,085 mc. 0,001 137005-003 AVORIO/IVORY RAL1013 x1 10 telaio tubo/tube frame 0,085 mc. 0,001 137008-003

great design · 137004-003 GRIGIO/GREY RAL7003 x1 10 telaio tubo/tube frame 0,085 mc. 0,001 137005-003 AVORIO/IVORY RAL1013 x1 10 telaio tubo/tube frame 0,085 mc. 0,001 137008-003

Documents
web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/MWS2015/Larocca.pdf · MYELOMA WORKSHOP Rome. Auditorium Parco della Musica September 23-26, 2015 Geriatric assessment

web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/MWS2015/Larocca.pdf · MYELOMA WORKSHOP Rome. Auditorium Parco della Musica September 23-26, 2015 Geriatric assessment

Documents
Slide 2 / 23 - web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S4-0… · slide 1 / 23 slide 2 / 23 page 1. undefined s4-04 lobular carcinoma in situ

Slide 2 / 23 - web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S4-0… · slide 1 / 23 slide 2 / 23 page 1. undefined s4-04 lobular carcinoma in situ

Documents
SABCS 2014 - web.oncoletter.chweb.oncoletter.ch/.../SABCS2014/S1-01.pdf · 2014 Dr. Di Leo: Consulting, Consultnig fees from AstraZeneca and Pfizer; Other Financial, Research Support

SABCS 2014 - web.oncoletter.chweb.oncoletter.ch/.../SABCS2014/S1-01.pdf · 2014 Dr. Di Leo: Consulting, Consultnig fees from AstraZeneca and Pfizer; Other Financial, Research Support

Documents
web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASH2014/ASH2014_80.pdf · Tx to at least one prior regumen and then developed PO s 60 days corn*tTtg their last

web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASH2014/ASH2014_80.pdf · Tx to at least one prior regumen and then developed PO s 60 days corn*tTtg their last

Documents
Nutmuttern / Locknuts - Kugellager, Wälzlager. ICBE · km06 m30x1.5 38 45 7 5 2 0,043 km07 m35x1.5 44 52 8 5 2 0,053 km08 m40x1.5 50 58 9 6 2,5 0,085 km09 m45x1.5 56 65 10 6 2,5

Nutmuttern / Locknuts - Kugellager, Wälzlager. ICBE · km06 m30x1.5 38 45 7 5 2 0,043 km07 m35x1.5 44 52 8 5 2 0,053 km08 m40x1.5 50 58 9 6 2,5 0,085 km09 m45x1.5 56 65 10 6 2,5

Documents
web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/MWS... ·  · 2015-09-24Common Themes Does patient need treatment If yes, are they fit or frail (2 drugs) Should

web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/MWS... ·  · 2015-09-24Common Themes Does patient need treatment If yes, are they fit or frail (2 drugs) Should

Documents
SABCS 2013 - oncoletterweb.oncoletter.ch/.../Kongressdateien/SABCS2013/S3-06.pdf · 2013. 12. 13. · Dr. Schnitt: Nothing to disclose. 2013 SAN ANTONIO BREAST CANCER SYMPOSIUM

SABCS 2013 - oncoletterweb.oncoletter.ch/.../Kongressdateien/SABCS2013/S3-06.pdf · 2013. 12. 13. · Dr. Schnitt: Nothing to disclose. 2013 SAN ANTONIO BREAST CANCER SYMPOSIUM

Documents
web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C05... · Rapido trial, results awaited Locally advanced Rectal Cancer International randomized multicentre

web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C05... · Rapido trial, results awaited Locally advanced Rectal Cancer International randomized multicentre

Documents
oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · Cycle 2 Cvcle3-6 Cycle7-24 Follow-Up Daratumumab infusions (First infusion includes pre-dose the before) Lenalidomide

oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · Cycle 2 Cvcle3-6 Cycle7-24 Follow-Up Daratumumab infusions (First infusion includes pre-dose the before) Lenalidomide

Documents
oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO... · 2017. 1. 21. · PRODIGE OE RECHERC*e GEMOX vs surveillance following surgery of localized biliary tract cancer:

oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO... · 2017. 1. 21. · PRODIGE OE RECHERC*e GEMOX vs surveillance following surgery of localized biliary tract cancer:

Documents
oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASH... · 2015. 12. 8. · Randomized, double-blind, placebo-controlled study in adult ß-thalasserupatients (including

oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASH... · 2015. 12. 8. · Randomized, double-blind, placebo-controlled study in adult ß-thalasserupatients (including

Documents
DSC 5266 - Willkommen bei oncoletter - Oncoletter, …web.oncoletter.ch/files/cto_layout/Kongressdateien/ASC… ·  · 2014-01-18Metastatic Gastric or Gastroesophageal Junction (GEJ)

DSC 5266 - Willkommen bei oncoletter - Oncoletter, …web.oncoletter.ch/files/cto_layout/Kongressdateien/ASC… ·  · 2014-01-18Metastatic Gastric or Gastroesophageal Junction (GEJ)

Documents